Aryl Hydrocarbon Hydroxylases
"Aryl Hydrocarbon Hydroxylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large group of cytochrome P-450 (heme-thiolate) monooxygenases that complex with NAD(P)H-FLAVIN OXIDOREDUCTASE in numerous mixed-function oxidations of aromatic compounds. They catalyze hydroxylation of a broad spectrum of substrates and are important in the metabolism of steroids, drugs, and toxins such as PHENOBARBITAL, carcinogens, and insecticides.
| Descriptor ID |
D001189
|
| MeSH Number(s) |
D08.244.453.005 D08.811.682.690.708.170.010 D12.776.422.220.453.010
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aryl Hydrocarbon Hydroxylases".
Below are MeSH descriptors whose meaning is more specific than "Aryl Hydrocarbon Hydroxylases".
This graph shows the total number of publications written about "Aryl Hydrocarbon Hydroxylases" by people in this website by year, and whether "Aryl Hydrocarbon Hydroxylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 5 | 0 | 5 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aryl Hydrocarbon Hydroxylases" by people in Profiles.
-
Daikenchuto (TU-100) alters murine hepatic and intestinal drug metabolizing enzymes in an in vivo dietary model: effects of gender and withdrawal. Pharmacol Res Perspect. 2017 10; 5(5).
-
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet. 2017 04; 25(4):432-438.
-
CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt. Nicotine Tob Res. 2016 May; 18(5):637-41.
-
Rhythmic expression of cytochrome P450 epoxygenases CYP4x1 and CYP2c11 in the rat brain and vasculature. Am J Physiol Cell Physiol. 2014 Dec 01; 307(11):C989-98.
-
Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014 05 01; 370(18):1763.
-
Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
-
Prevalence of CYP2C8 polymorphisms in a North Indian population. Genet Mol Res. 2013 Jul 08; 12(3):2260-6.
-
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31; 382(9894):790-6.
-
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics. 2013; 14 Suppl 3:S11.
-
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenet Genomics. 2013 Apr; 23(4):228-31.